News Daily News Who Benefits Most From Semaglutide and How Long Will That Take? Shelley Wood December 19, 2023
News Daily News Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk Todd Neale December 12, 2023
News Conference News HFSA 2023 Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis Todd Neale October 11, 2023
News Daily News Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs Caitlin E. Cox October 06, 2023
News Daily News PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY Michael O'Riordan September 29, 2023
News Daily News European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba Michael O'Riordan September 15, 2023
News Daily News Vegetarian Diets May Curb Cardiometabolic Risk: Meta-analysis Caitlin E. Cox August 01, 2023
News Daily News New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization Michael O'Riordan July 20, 2023
News Conference News ADA 2023 Oral, Daily Semaglutide Cuts Pounds in Nondiabetic Patients: OASIS 1 Shelley Wood June 29, 2023
News Features Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar L.A. McKeown May 12, 2023
News Daily News To Improve CV Care in US South Asians, Understand Unique ASCVD Risks: ACC Yael L. Maxwell April 12, 2023
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ACC 2023 STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy L.A. McKeown March 04, 2023
News Daily News Obesity and CVD: New Review Highlights Where Tools and Meds Fall Short Shelley Wood January 31, 2023